Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment

Liver International

Volumn 30, Issue 2, 2010, Pages 311-318

  Chang, Jin Hai ^a   Kato, Naoya ^b   Muroyama, Ryosuke ^b   Taniguchi, Hiroyoshi ^a   Guleng, Bayasi ^a   Dharel, Narayan ^a   Shao, Run Xuan ^a   Tateishi, Keisuke ^a   Jazag, Amarsanaa ^a   Kawabe, Takao ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Double stranded RNA activated protein kinase; Hepatitis C virus; Interferon; Interferon stimulated gene; RNA interference

Indexed keywords

ALPHA INTERFERON; LUCIFERASE; PROTEIN KINASE R;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSFECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REPLICON; REPORTER GENE; RNA INTERFERENCE; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; EIF-2 KINASE; GENE EXPRESSION REGULATION, VIRAL; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION; VIRUS REPLICATION;

EID: 77950606173     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02144.x     Document Type: Article

References (37)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
2. Saito I, Miyamura T, Ohbayashi A. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990, 87:6547-9.
3. Shiratori Y, Shiina S, Imamura M. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995, 22:1027-33.
4. Omata M, Yokosuka O, Takano S. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991, 338:914-5.
5. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82.
6. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004, 39:5-19.
7. Butcher SJ, Grimes JM, Makeyev EV, Bamford DH, Stuart DI. A mechanism for initiating RNA-dependent RNA polymerization. Nature 2001, 410:235-40.
8. Delhem N, Sabile A, Gajardo R. Activation of the interferon-inducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein. Oncogene 2001, 20:5836-45.
9. Dey M, Cao C, Dar AC. Mechanistic link between PKR dimerization, autophosphorylation, and eIF2alpha substrate recognition. Cell 2005, 122:901-13.
10. Fukushi S, Okada M, Kageyama T, Hoshino FB, Katayama K. Specific interaction of a 25-kilodalton cellular protein, a 40S ribosomal subunit protein, with the internal ribosome entry site of hepatitis C virus genome. Virus Genes 1999, 19:153-61.
11. Otto GA, Puglisi JD. The pathway of HCV IRES-mediated translation initiation. Cell 2004, 119:369-80.
12. Siridechadilok B, Fraser CS, Hall RJ, Doudna JA, Nogales E. Structural roles for human translation factor eIF3 in initiation of protein synthesis. Science 2005, 310:1513-5.
13. Yokota T, Sakamoto N, Enomoto N. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 2003, 4:602-8.
14. Wakita T, Pietschmann T, Kato T. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11:791-6.
15. Tanabe Y, Sakamoto N, Enomoto N. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 2004, 189:1129-39.
16. Miyagishi M, Taira K. U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 2002, 20:497-500.
17. Jazag A, Ijichi H, Kanai F. Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta. Oncogene 2005, 24:662-71.
18. Ohashi M, Kanai F, Ueno H. Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo. Gut 1999, 44:366-71.
19. Aoyagi K, Ohue C, Iida K. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999, 37:1802-8.
20. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3:47-52.
21. Choo QL, Kuo G, Weiner AJ. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-62.
22. Lohmann V, Korner F, Koch J. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-3.
23. Lindenbach BD, Evans MJ, Syder AJ. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-6.
24. Cai Z, Zhang C, Chang KS. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol 2005, 79:13963-73.
25. Zhong J, Gastaminza P, Cheng G. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005, 102:9294-9.
26. Chang KS, Cai Z, Zhang C. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol 2006, 80:7364-74.
27. Itsui Y, Sakamoto N, Kurosaki M. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J Viral Hepat 2006, 13:690-700.
28. Tokumoto Y, Hiasa Y, Horiike N. Hepatitis C virus expression and interferon antiviral action is dependent on PKR expression. J Med Virol 2007, 79:1120-7.
29. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006, 41:17-27.
30. Khakoo S, Glue P, Grellier L. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998, 46:563-70.
31. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003, 34:263-74.
32. Liu WL, Su WC, Cheng CW. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus. J Infect Dis 2007, 196:425-34.
33. Saunders LR, Barber GN. The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J 2003, 17:961-83.
34. Scadden AD, Smith CW. A ribonuclease specific for inosine-containing RNA: a potential role in antiviral defence? EMBO J 1997, 16:2140-9.
35. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107-10.
36. Gimenez-Barcons M, Wang C, Chen M. The oncogenic potential of hepatitis C virus NS5A sequence variants is associated with PKR regulation. J Interferon Cytokine Res 2005, 25:152-64.
37. Noguchi T, Satoh S, Noshi T. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol Immunol 2001, 45:829-40.